[Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea].
OBJECTIVE
We investigated the five-year survival outcomes of a large cohort of hepatocellular carcinoma (HCC) patients who were treated at a single institute, and this is a follow-up study of a previous report.


METHODS
Nine hundred four HCC patients who were treated at the National Cancer Center Korea were enrolled and they were followed till February 2007.


RESULTS
The mean age of the patients was 56.0 years and 731 patients were male. Six hundred seventy-seven (74.9%) patients died and the overall 5-year survival rate (5-YSR) was 23.9%. The 5-YSRs of the patients with modified UICC stage I, II and III were 61.2%, 54.4% and 18.4%, respectively, and the median survival time was 4.3 and 3.7 months for the stage IVa and IVb patients, respectively. For the analysis of the treatment modality, surgical resection showed significantly better outcomes for the five-year survival as compared with transcatheter arterial chemoembolization (TACE) for Child-Pugh A patients with modified UICC stage I or II disease (80.1% vs 52.8%, respectively, P<.001), or stage III disease (60.7% vs 17.0%, respectively, P<.001). For patients with advanced stage IVb disease, TACE, systemic chemotherapy and radiotherapy increased the median survival period more than conservative management for the Child-Pugh class A patients. The serum alpha-fetoprotein level, portal vein tumor thrombosis, the Child-Pugh class, the tumor stage, the tumor type and symptoms were related to the prognosis.


CONCLUSIONS
This study presented, for the first time, the 5-YSRs of a cohort of HCC patients.
Park
Kyung Woo
KW
Center for Cancer Prevention and Detection, National Cancer Center, Goyang, Korea.
Park
Joong Won
JW
Kim
Tae Hyun
TH
Choi
Jun Il
JI
Kim
Seong Hoon
SH
Park
Hong Suk
HS
Park
Sang Jae
SJ
Lee
Woo Jin
WJ
Shin
Hae Lim
HL
Kim
Chang Min
CM
D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000401:mortality* / Q000601:surgery; D016461:Chemoembolization, Therapeutic; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007723:Korea; D008113:Liver Neoplasms / Q000209:etiology / Q000401:mortality* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D020266:Radiotherapy, Conformal; D012720:Severity of Illness Index; D015996:Survival Rate